Alleviating effects of AS1892802, a rho kinase inhibitor, on osteoarthritic disorders in rodents

Journal of Pharmacological Sciences

Volumn 115, Issue 4, 2011, Pages 481-489

  Takeshita, Nobuaki ^a   Yoshimi, Eiji ^a   Hatori, Chie ^a   Kumakura, Fumiyo ^a   Seki, Nobuo ^a   Shimizu, Yasuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cartilage; Inflammation; Osteoarthritis; Pain; Rho kinase inhibitor

Indexed keywords

ANALGESIC AGENT; AS 1892802; BRADYKININ; CHONDROPROTECTIVE AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; PROSTAGLANDIN E2; PROTEIN SERINE THREONINE KINASE; RHO ASSOCIATED COILED COIL KINASE I; RHO ASSOCIATED COILED COIL KINASE II; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE INJURY; CELL DIFFERENTIATION; CHONDROPROTECTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; IN VITRO STUDY; KNEE OSTEOARTHRITIS; KNEE PAIN; MOUSE; NONHUMAN; PAIN ASSESSMENT; PROSTAGLANDIN RELEASE; RAT; WEIGHT BEARING;

EID: 79955002025     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10319FP     Document Type: Article

References (46)

1. Poole AR, Rizkalla G, Ionescu M, Reiner A, Brooks E, Rorabeck C, et al. Osteoarthritis in the human knee: a dynamic process of cartilage matrix degradation, synthesis and reorganisaton. Agents Actions. 1993;39 Suppl:3-13.
2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16: 137-162. (Pubitemid 351222155)
3. Schnitzer TJ, American College of Rheumatology. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage. 2002;23:S24-S30. (Pubitemid 34476936)
4. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885-1893. (Pubitemid 26119224)
5. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28: 296-302. (Pubitemid 46818464)
6. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17-24. (Pubitemid 47220442)
7. Yoshikawa H, Yoshioka K, Nakase T, Itoh K. Stimulation of ectopic bone formation in response to BMP-2 by Rho kinase inhibitor: a pilot study. Clin Orthop Relat Res. 2009;467:3087-3095.
8. Wang G, Woods A, Sabari S, Pagnotta L, Santon LA, Beier F. RhoA/ROCK signaling suppresses hypertrophic chondrocyte differentiation. J Biol Chem. 2004;279:13205-13214. (Pubitemid 38445899)
9. Appleton CTG, Usmani SE, Mort JS, Beier F. Rho/ROCK and MEK/ERK activation by transforming growth factor-α induces articular cartilage degradation. Lab Invest. 2010;90:20-30.
10. Novakofski K, Boehm A, Fortier L. The small GTPase Rho mediates articular chondrocyte phenotype and morphology in response to interleukin-1α and insulin-like growth factor-I. J Orthop Res. 2009;27:58-64.
11. Haudenschild DR, Chen J, Pang N, Lots MK, D'Lima DD. Rho kinase-dependent activation of Sox9 in chondrocytes. Arthritis Rheum. 2010;62:191-200.
12. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10:712-718. (Pubitemid 38937636)
13. Büyükafşar K, Yalçin I, Kurt AH, Tiftik RN, Sahan-Firat S, Aksu F. Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice. Eur J Pharmacol. 2006;541:49-52. (Pubitemid 43922439)
14. Tatsumi S, Mabuchi T, Katano T, Matsumura S, Abe T, Hidaka H, et al. Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alaninerich C-kinase substrate (MARCKS). Neuroscience. 2005;131: 491-498. (Pubitemid 40222456)
15. Yoshimi E, Kumakura F, Hatori C, Hamachi E, Iwashita A, Ishii N, et al. Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and non-inflammatory arthritis. J Pharmacol Exp Ther. 2010;334:955-963.
16. Nakamura Y, Takarada T, Kodama A, Hinoi E, Yoneda Y. Predominant promotion by tacrolimus of chondrogenic differentiation to proliferating chondrocytes. J Pharmacol Sci. 2009;109: 413-423.
17. Guingamp C, Geogout-Potttie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40:1670-1679. (Pubitemid 27426161)
18. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemon AJ, Hoyland JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 2001;9:751-760. (Pubitemid 33076767)
19. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003;11:821-830. (Pubitemid 37407598)
20. Gotoh S, Onaya J, Abe M, Miyazaki K, Hamai A, Horie K, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52:817-822. (Pubitemid 23328695)
21. Nishigaki F, Sakuma S, Ogawa T, Miyata S, Ohkubo T, Goto T. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol. 2002; 437:123-128. (Pubitemid 34219472)
22. Bendele AM, Hulman JF. Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum. 1988;31:561-565.
23. Walton M. Degenerative joint disease in the mouse knee; radiological and morphological observations. J Pathol. 1977;123: 97-107. (Pubitemid 8198649)
24. Walton M. Studies of degenerative joint disease in the mouse knee joint; histological observations. J Pathol. 1977;123:109-122. (Pubitemid 8198650)
25. Pond MJ, Nuki G. Experimentally induced osteoarthritis in the dog. Ann Rheum Dis. 1973;32:387-388.
26. Moskowitz RW, Davis W, Sammaraco J, Martens M, Baker J, Mayor M, et al. Experimentally induced degenerative joint lesions following partial menisectomy in the rabbit. Arthritis Rheum. 1973;16:397-405.
27. Bendele AM, White SL. Early histopathologic and ultrastructural alterations in femorotibial joints of partial medial menisectomized guinea pigs. Vet Pathol. 1987;24:436-443.
28. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol. 1999;27:134-142. (Pubitemid 29075759)
29. Botter SM, van Osch GJ, Waarsing JH, van der Linden JC, Verhaar JA, Pols HA, et al. Cartilage damage pattern in relation to subchondral plate thickness in a collagenase-induced model of osteoarthritis. Osteoarthritis Cartilage. 2008;16:506-514. (Pubitemid 351426268)
30. Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B. Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum. 1999;42:2094-2102. (Pubitemid 30263592)
31. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M, Fukunari A, et al. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats. J Vet Med Sci. 2003;65:1195-1199. (Pubitemid 41380043)
32. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? Neurosci Lett. 2004;370:236-240.
33. Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005;280:11626-11634. (Pubitemid 40418476)
34. Woods A, Wang G, Beier F. Regulation of chondrocyte differentiation by the actin cytoskeleton and adhesive interactions. J Cell Physiol. 2007;213:1-8. (Pubitemid 47378786)
35. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39: 237-246. (Pubitemid 34626067)
36. Kolomytkin OV, Marino AA, Waddell DD, Mathis JM, Wolf RE, Sadasivan KK, et al. IL-1beta-induced production of metalloproteinases by synovial cells depends on gap junction conductance. Am J Physiol cell Physiol. 2002;282:C1254-C1260. (Pubitemid 34663073)
37. Singh R, Wang B, Shirvaikar S, Khan S, Kamat S, Schelling JR, et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J Clin Invest. 1999;103:1561-1570.
38. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004;37:537-546. (Pubitemid 38953381)
39. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003;11:738-746. (Pubitemid 37184492)
40. Nakajima M, Katayama K, Tamechika I, Hayashi K, Amano Y, Uehata M, et al. WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility. Clin Exp Pharmacol Physiol. 2003;30:457-463. (Pubitemid 36836561)
41. Yoshimi E, Yamamoto H, Furuichi, Y, Takseshita N. Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. J Pharmacol Sci. 2010;114:119-122.
42. Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Pathol Oral Radiol Endod. 2002;94:328-332. (Pubitemid 41124768)
43. SundarRaj N, Kinchington PR, Wessel H, Goldblatt B, Hassell J, Vergnes JP, et al. A Rho-associated protein kinase: differentially distributed in limbal and corneal epithelia. Invest Ophthalmol Vis Sci. 1998;39:1266-1272. (Pubitemid 28247364)
44. Pan ZK, Ye RD, Christiansen SC, Jagels MA, Bokoch GM, Zuraw BL. Role of the Rho GTPase in bradykinin-stimulated nuclear factor-kappaB activation and IL-1beta gene expression in cultured human epithelial cells. J Immunol. 1998;160: 3038-3045. (Pubitemid 28136761)
45. Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res. 2008;57:351-561.
46. Gotoh S, Onaya J, Abe M, Miyazaki K, Hamai A, Horie K, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52:817-822. (Pubitemid 23328695)